ArticleNPJ digital medicine2025
The structure-preserving spectral graph neural network for dual kinase inhibitors and synergy scoring in gastric cancer.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Spatial-spectral fusion enables drug repositioning by capturing indirect and long-range associations in biological networks.Bioinformatics (Oxford, England) · 2026Article
- DS-transformer: a dual-stream transformer for lithium-ion battery state-of-health estimation via cross-attention fusion of discharge curves and impedance features.Scientific reports · 2026Article
- Interpretable multimodal machine learning for injury risk stratification in adolescent athletes: integrating kinematic, physiological, and load data with SHAP/LIME explainability.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The therapeutic targeting of kinase signaling pathways represents a pivotal strategy in gastric cancer, yet the rational design of single agents capable of dual-kinase inhibition remains a challenge in precision oncology. Here, we develop the DuoKinaseNet, a dual-task spectral graph neural network that integrates global topological information from a heterogeneous biomedical graph to enable structure-preserving prediction of drug-kinase interactions. The core innovation of our model is the Structure-Preserving Spectral Expansion (SPSE) module, which injects global graph topology from a biomedical knowledge graph into the learning process via spectral coordinates and diffusion-distance biased attention. Evaluated on a comprehensive dataset curated from DrugBank, DuoKinaseNet achieves state-of-the-art performance, particularly on the challenging "unseen protein" benchmark, with an AUC-ROC of 0.903 for HER2 and 0.895 for FGFR2b. It significantly outperforms a wide range of baseline models, including 3D-aware methods and single-task variants, empirically validating the synergistic benefits of the dual-task learning and SPSE frameworks.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.